{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:45:58Z","timestamp":1790959558587,"version":"4.1.0"},"reference-count":327,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jaip.2026.01.022","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:37:31Z","timestamp":1772606251000},"page":"583-596.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Biologics Use in Eosinophilic Lung Disease: Controversies and Consensus"],"prefix":"10.1016","volume":"14","author":[{"given":"Luis","family":"P\u00e9rez de Llano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Dacal","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian Muhammad Salman","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njira","family":"Lugogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2026.01.022_bib1","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib2","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib3","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2026.01.022_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.rmed.2018.03.016","article-title":"Blood eosinophil levels as a biomarker in COPD","volume":"138","author":"Brusselle","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib198","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.chest.2023.04.028","article-title":"Are we ready for asthma remission as a clinical outcome?","volume":"164","author":"Lugogo","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2026.01.022_bib199","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3390\/ijms25020730","article-title":"Airways type-2 related disorders: multiorgan, systemic or syndemic disease?","volume":"25","author":"Giombi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaip.2026.01.022_bib6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.iac.2023.01.002","article-title":"Eosinophilic lung diseases","volume":"43","author":"Cottin","year":"2023","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2026.01.022_bib7","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1111\/all.16303","article-title":"Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: effects on and beyond eosinophils","volume":"79","author":"Buchheit","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bib8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaip.2024.10.036","article-title":"Dupilumab use in patients with hypereosinophilic syndromes: a multicenter case series and review of the literature","volume":"13","author":"Ezekwe","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib10","doi-asserted-by":"crossref","first-page":"00576","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2026.01.022_bib11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s10238-023-01267-y","article-title":"Efficacy of omalizumab in adult patients with allergic bronchopulmonary aspergillosis: a multicentre study in China","volume":"24","author":"Chen","year":"2024","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00061-2024","article-title":"Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis\/mycoses","volume":"63","author":"Agarwal","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2026.01.022_bib13","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib14","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00408-020-00336-3","article-title":"Real-life study of mepolizumab in idiopathic chronic eosinophilic pneumonia","volume":"198","author":"Brenard","year":"2020","journal-title":"Lung"},{"key":"10.1016\/j.jaip.2026.01.022_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2021.07.1160","article-title":"When steroids fail: a population-based review of biologic therapies in the management of recalcitrant eosinophilic pneumonia","volume":"160","author":"Askin","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2026.01.022_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/JAA.S343272","article-title":"Anti-IL-5 agents for the treatment of idiopathic chronic eosinophilic pneumonia: a case series","volume":"15","author":"Tashiro","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bib18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/02770903.2018.1543434","article-title":"Anti-interleukin (IL)-5 as a steroid-sparing agent in chronic eosinophilic pneumonia","volume":"57","author":"Sarkis","year":"2020","journal-title":"J Asthma"},{"key":"10.1016\/j.jaip.2026.01.022_bib19","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1016\/j.jaip.2020.06.053","article-title":"Effect of mepolizumab alone in chronic eosinophilic pneumonia relapse: a case report","volume":"8","author":"Ciuffreda","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2020.08.1010","article-title":"Steroid dependent chronic eosinophilic pneumonia: a win for IL-5 antagnonism in an active duty service member","volume":"158","author":"Askin","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2026.01.022_bib21","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.7573\/dic.2020-5-3","article-title":"Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance","volume":"9","author":"Kisling","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.jaip.2026.01.022_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.514","article-title":"Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty","volume":"8","author":"Otoshi","year":"2020","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.18176\/jiaci.0671","article-title":"Efficacy of mepolizumab extended interval dosing for 2 asthmatic patients with chronic eosinophilic pneumonia","volume":"31","author":"Sato","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2021.08.271","article-title":"M122 Mepolizumab: A steroid alternative for chronic eosinophilic pneumonia","volume":"127","author":"Benipal","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib25","article-title":"Mepolizumab and dupilumab as a replacement to systemic glucocorticoids for the treatment of chronic eosinophilic pneumonia and allergic bronchopulmonary aspergillosis - case series, Almoosa specialist hospital","volume":"34","author":"Eldaabossi","year":"2021","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib26","article-title":"Chronic eosinophilic pneumonia: when corticosteroids are not enough","volume":"203","author":"Mckillion","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib27","series-title":"Successful use of mepolizumab for steroid-dependent chronic eosinophilic pneumonia","author":"Cyca","year":"2022"},{"key":"10.1016\/j.jaip.2026.01.022_bib28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.12688\/f1000research.130939.3","article-title":"Case report: mepolizumab in the treatment of idiopathic chronic eosinophilic pneumonia","volume":"12","author":"Daboussi","year":"2023","journal-title":"F1000Res"},{"key":"10.1016\/j.jaip.2026.01.022_bib29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00508-024-02406-5","article-title":"Healing chronic idiopathic eosinophilic pneumonia using mepolizumab alone without corticosteroids","volume":"137","author":"Moritz","year":"2025","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.jaip.2026.01.022_bib30","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.jaip.2018.06.017","article-title":"A case of chronic eosinophilic pneumonia successfully treated with mepolizumab","volume":"6","author":"To","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib31","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib32","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.1147","article-title":"Tezepelumab treatment for allergic bronchopulmonary aspergillosis","volume":"11","author":"Ogata","year":"2023","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib34","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.jaip.2023.05.026","article-title":"Allergic bronchopulmonary aspergillosis successfully treated with tezepelumab","volume":"11","author":"Matsuno","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib35","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jaip.2018.11.024","article-title":"Allergic bronchopulmonary aspergillosis successfully treated with benralizumab","volume":"7","author":"Soeda","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib36","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.anai.2025.10.019","article-title":"Benralizumab for patients with hypereosinophilic syndrome: a randomized, double-blind, placebo-controlled phase 3 trial (NATRON)","volume":"135","author":"Ogbogu","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib37","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jaip.2018.03.011","article-title":"Eosinophilic pneumonias","volume":"6","author":"Allen","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib38","article-title":"Acute and chronic eosinophilic pneumonia: an overview","volume":"11","author":"Carbone","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaip.2026.01.022_bib39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.alit.2019.05.006","article-title":"Eosinophilic pneumonia: A review of the previous literature, causes, diagnosis, and management","volume":"68","author":"Suzuki","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2026.01.022_bib40","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1164\/rccm.2112056","article-title":"Idiopathic acute eosinophilic pneumonia: a study of 22 patients","volume":"166","author":"Philit","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib41","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1378\/chest.07-2669","article-title":"Alterations in smoking habits are associated with acute eosinophilic pneumonia","volume":"133","author":"Uchiyama","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2026.01.022_bib42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1183\/09031936.00221811","article-title":"Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia","volume":"41","author":"Rhee","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2026.01.022_bib43","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/resp.12342","article-title":"Clinical implications of initial peripheral eosinophilia in acute eosinophilic pneumonia","volume":"19","author":"Jhun","year":"2014","journal-title":"Respirology"},{"key":"10.1016\/j.jaip.2026.01.022_bib44","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.chest.2017.03.001","article-title":"Acute Eosinophilic pneumonia: correlation of clinical characteristics with underlying cause","volume":"152","author":"De Giacomi","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2026.01.022_bib45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.amjms.2022.10.003","article-title":"A comparative analysis of acute eosinophilic pneumonia associated with smoking and vaping","volume":"365","author":"Bonnier","year":"2023","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jaip.2026.01.022_bib46","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1056\/NEJMe1912032","article-title":"Vaping-induced acute lung injury","volume":"382","author":"Christiani","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib47","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000050532","article-title":"Increased interleukin-5 levels in bronchoalveolar lavage fluid is a major factor for eosinophil accumulation in acute eosinophilic pneumonia","volume":"68","author":"Nakahara","year":"2001","journal-title":"Respiration"},{"key":"10.1016\/j.jaip.2026.01.022_bib48","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1398-9995.2004.00492.x","article-title":"Elevated interleukin-18 levels in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia","volume":"59","author":"Katoh","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bib49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2332\/allergolint.12-OA-0439","article-title":"Clinical significance of interleukin 33 (IL-33) in patients with eosinophilic pneumonia","volume":"62","author":"Mato","year":"2013","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2026.01.022_bib50","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.alit.2020.09.013","article-title":"Clinical significance of invariant natural killer T cells and IL-5 in acute eosinophilic pneumonia","volume":"70","author":"Yoshida","year":"2021","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2026.01.022_bib51","doi-asserted-by":"crossref","first-page":"114s","DOI":"10.1183\/09031936.01.18s320114","article-title":"Comparison of registries of interstitial lung diseases in three European countries","volume":"32","author":"Thomeer","year":"2001","journal-title":"Eur Respir J Suppl"},{"key":"10.1016\/j.jaip.2026.01.022_bib52","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009688","article-title":"Drug-induced eosinophilic pneumonia: a review of 196 case reports","volume":"97","author":"Bartal","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaip.2026.01.022_bib53","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00408-017-0048-8","article-title":"Possible role of IL-25 in eosinophilic lung inflammation in patients with chronic eosinophilic pneumonia","volume":"195","author":"Katoh","year":"2017","journal-title":"Lung"},{"key":"10.1016\/j.jaip.2026.01.022_bib54","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.4049\/jimmunol.155.4.2194","article-title":"Eosinophil adhesion to vascular cell adhesion molecule-1 activates superoxide anion generation","volume":"155","author":"Nagata","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib55","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/cea.13382","article-title":"Critical role of CCL4 in eosinophil recruitment into the airway","volume":"49","author":"Kobayashi","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bib56","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S1081-1206(10)61269-0","article-title":"Leukotriene D4 and eosinophil transendothelial migration, superoxide generation, and degranulation via beta2 integrin","volume":"93","author":"Saito","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib79","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12890-024-02868-3","article-title":"Monoclonal antibodies in idiopathic chronic eosinophilic pneumonia: a scoping review","volume":"24","author":"Murillo","year":"2024","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib57","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3346\/jkms.2012.27.10.1261","article-title":"Successful treatment of chronic eosinophilic pneumonia with anti-IgE therapy","volume":"27","author":"Shin","year":"2012","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jaip.2026.01.022_bib58","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1378\/chest.12-2035","article-title":"Can omalizumab be effective in chronic eosinophilic pneumonia?","volume":"143","author":"Domingo","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2026.01.022_bib59","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1378\/chest.11-1881","article-title":"Omalizumab as a steroid-sparing agent in chronic eosinophilic pneumonia","volume":"142","author":"Kaya","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2026.01.022_bib60","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.arbr.2018.05.004","article-title":"Response to omalizumab in a patient with chronic eosinophilic pneumonia and poor response to corticosteroids","volume":"54","author":"Lavi\u00f1a-Soriano","year":"2018","journal-title":"Arch Bronconeumol (Engl Ed)"},{"key":"10.1016\/j.jaip.2026.01.022_bib61","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/02770903.2018.1534966","article-title":"Favorable response to asthma-dosed subcutaneous mepolizumab in eosinophilic pneumonia","volume":"56","author":"Lin","year":"2019","journal-title":"J Asthma"},{"key":"10.1016\/j.jaip.2026.01.022_bib62","article-title":"A case of relapsing chronic eosinophilic pneumonia treated by Omalizumab","volume":"41","author":"Nehme","year":"2023","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib63","article-title":"Chronic eosinophilic pneumonia and new biological therapies [article in Spanish]","volume":"3","author":"Morena Valles","year":"2021","journal-title":"Open Respir Arch"},{"key":"10.1016\/j.jaip.2026.01.022_bib64","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.12998\/wjcc.v10.i18.6105","article-title":"Successful treatment of acute relapse of chronic eosinophilic pneumonia with benralizumab and without corticosteroids: a case report","volume":"10","author":"Izhakian","year":"2022","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.jaip.2026.01.022_bib65","article-title":"Two years follow-up of relapsing eosinophilic pneumonia with concomitant severe asthma successfully treated with benralizumab: a case report and brief review of the literature","volume":"41","author":"Angeletti","year":"2023","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.810","article-title":"Benralizumab use in chronic eosinophilic pneumonia with eosinophilic bronchiolitis and chronic airway infection","volume":"9","author":"Takano","year":"2021","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib67","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.anai.2021.02.016","article-title":"Relapsing chronic eosinophilic pneumonia treated successfully with benralizumab","volume":"126","author":"Ricketti","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib68","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.alit.2020.07.005","article-title":"Benralizumab as initial treatment for chronic eosinophilic pneumonia","volume":"70","author":"Yazawa","year":"2021","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2026.01.022_bib69","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1002\/ppul.25511","article-title":"Reverse butterfly pattern image with eosinophilia: effective treatment with benralizumab-a case report","volume":"56","author":"Ben-David","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2026.01.022_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2019.08.436","article-title":"M401 Benralizumab for unresponsive steroid-dependent chronic eosinophilic pneumonia","volume":"123","author":"Garcia-Saucedo","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib71","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2169\/internalmedicine.3606-19","article-title":"Promising effects of benralizumab on chronic eosinophilic pneumonia","volume":"59","author":"Isomoto","year":"2020","journal-title":"Intern Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2020.05.195","article-title":"Eosinophilic pneumonia when steroids are not the answer: case report","volume":"157","author":"Braga","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2026.01.022_bib73","article-title":"Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia","volume":"30","author":"Izumo","year":"2020","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib74","article-title":"Exploring the efficacy of benralizumab in chronic eosinophilic pneumonia following corticosteroid therapeutic failure: a case report","volume":"17","author":"De La O Villalobos","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2026.01.022_bib75","article-title":"Benralizumab treatment and 3-dimensional bronchial tree changes in chronic eosinophilic pneumonia","volume":"4","author":"Kai","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaip.2026.01.022_bib76","first-page":"857","article-title":"Dupilumab suppresses relapsing chronic eosinophilic pneumonia with severe asthma","volume":"85","author":"Masumoto","year":"2023","journal-title":"Nagoya J Med Sci"},{"key":"10.1016\/j.jaip.2026.01.022_bib77","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1002\/ppul.25096","article-title":"Dupilumab for chronic eosinophilic pneumonia","volume":"55","author":"Fowler","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2026.01.022_bib78","doi-asserted-by":"crossref","first-page":"154","DOI":"10.18176\/jiaci.0468","article-title":"Long-term treatment with anti-interleukin 5 antibodies in a patient with chronic eosinophilic pneumonia","volume":"30","author":"Shimizu","year":"2020","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib80","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/all.15544","article-title":"Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes","volume":"78","author":"Valent","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bib81","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaci.2010.03.035","article-title":"Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence","volume":"126","author":"Crane","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib200","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib83","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib84","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.jaip.2022.03.034","article-title":"Clinical profile and treatment in hypereosinophilic syndrome variants: a pragmatic review","volume":"10","author":"Requena","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib85","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/ACI.0000000000001078","article-title":"Hypereosinophilia: clinical and therapeutic approach in 2025","volume":"25","author":"Taurisano","year":"2025","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib86","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/ajh.27287","article-title":"World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Shomali","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2026.01.022_bib87","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1056\/NEJMoa031261","article-title":"Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis","volume":"349","author":"Pl\u00f6tz","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib88","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaci.2003.10.049","article-title":"Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes","volume":"113","author":"Garrett","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib89","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1016\/j.jaip.2021.07.050","article-title":"Safety and efficacy of mepolizumab in hypereosinophilic syndrome: an open-label extension study","volume":"9","author":"Gleich","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib90","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jaip.2025.03.016","article-title":"Long-term efficacy and safety of benralizumab treatment for PDGFRA-negative hypereosinophilic syndrome","volume":"13","author":"Kuang","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib91","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaip.2022.02.006","article-title":"An international, retrospective study of off-label biologic use in the treatment of hypereosinophilic syndromes","volume":"10","author":"Chen","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2025.1605397","article-title":"Steroid-sparing benefits of biologic use in hypereosinophilic syndrome and substantial disease burden across subtypes","volume":"6","author":"Hwee","year":"2025","journal-title":"Front Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bib93","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jaci.2024.12.1085","article-title":"Mepolizumab in patients with lymphoid-variant hypereosinophilic syndrome: a multicenter prospective study","volume":"155","author":"Catherine","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib94","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jpeds.2009.01.058","article-title":"Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5","volume":"155","author":"Mehr","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaip.2026.01.022_bib95","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/pai.12809","article-title":"Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood","volume":"29","author":"Schwarz","year":"2018","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib96","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.anai.2022.04.031","article-title":"Treatment of a 4-year-old boy with mepolizumab for lymphocytic hypereosinophilic syndrome","volume":"129","author":"Cascio","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib201","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaip.2020.08.034","article-title":"Successful treatment of idiopathic hypereosinophilic syndrome with benralizumab in a pediatric patient","volume":"9","author":"Forero Molina","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib97","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4103\/ijmr.IJMR_1187_19","article-title":"Allergic bronchopulmonary aspergillosis","volume":"151","author":"Agarwal","year":"2020","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.jaip.2026.01.022_bib98","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib100","first-page":"1839","article-title":"Anti IgE antibody as treatment of allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis","volume":"18","author":"Zicari","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jaip.2026.01.022_bib101","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.jaip.2023.04.009","article-title":"Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in adults with bronchial asthma: a systematic review of global data","volume":"11","author":"Agarwal","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib203","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1111\/cea.12595","article-title":"Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fibrosis: systematic review and meta-analysis","volume":"45","author":"Maturu","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bib204","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1034\/j.1399-3003.2000.016003464.x","article-title":"Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis","volume":"16","author":"Mastella","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2026.01.022_bib212","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaip.2014.08.007","article-title":"Allergic bronchopulmonary aspergillosis","volume":"2","author":"Greenberger","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib102","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1056\/NEJMra2027424","article-title":"Aspergillus infections","volume":"385","author":"Thompson","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib103","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.2741\/990","article-title":"Immunopathogenesis of allergic bronchopulmonary aspergillosis and airway remodeling","volume":"8","author":"Kauffman","year":"2003","journal-title":"Front Biosci"},{"key":"10.1016\/j.jaip.2026.01.022_bib104","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.alit.2015.04.004","article-title":"ILC2s and fungal allergy","volume":"64","author":"Kita","year":"2015","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2026.01.022_bib105","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41577-022-00704-5","article-title":"Heterogeneity of type 2 innate lymphoid cells","volume":"22","author":"Spits","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib106","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/cea.12354","article-title":"Pattern recognition pathways leading to a Th2 cytokine bias in allergic bronchopulmonary aspergillosis patients","volume":"45","author":"Becker","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bib107","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1165\/rcmb.2014-0333OC","article-title":"Suppression of epithelial signal transducer and activator of transcription 1 activation by extracts of Aspergillus fumigatus","volume":"53","author":"Bhushan","year":"2015","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaip.2026.01.022_bib108","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1165\/rcmb.2015-0062OC","article-title":"Role of Aspergillus fumigatus in triggering protease-activated receptor-2 in airway epithelial cells and skewing the cells toward a T-helper 2 bias","volume":"54","author":"Homma","year":"2016","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaip.2026.01.022_bib109","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00386-2024","article-title":"Th2-skewed peripheral T-helper cells drive B-cells in allergic bronchopulmonary aspergillosis","volume":"63","author":"Luo","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2026.01.022_bib205","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13223-016-0152-y","article-title":"Genetic susceptibility to allergic bronchopulmonary aspergillosis in asthma: a genetic association study","volume":"12","author":"Overton","year":"2016","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib206","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-7961-4-3","article-title":"IL-4 alpha chain receptor (IL-4Ralpha) polymorphisms in allergic bronchopulmonary aspergillosis","volume":"4","author":"Knutsen","year":"2006","journal-title":"Clin Mol Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bib110","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1086\/429964","article-title":"Influence of interleukin-10 on Aspergillus fumigatus infection in patients with cystic fibrosis","volume":"191","author":"Brouard","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaip.2026.01.022_bib111","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1744-313X.2006.00616.x","article-title":"Cytokine profiling of pulmonary aspergillosis","volume":"33","author":"Sambatakou","year":"2006","journal-title":"Int J Immunogenet"},{"key":"10.1016\/j.jaip.2026.01.022_bib209","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1183\/13993003.01475-2015","article-title":"A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma","volume":"47","author":"Agarwal","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2026.01.022_bib112","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1164\/rccm.200805-737OC","article-title":"Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the Fungal Asthma Sensitization Trial (FAST) study","volume":"179","author":"Denning","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib113","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3109\/02770903.2012.662568","article-title":"Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization","volume":"49","author":"Chishimba","year":"2012","journal-title":"J Asthma"},{"key":"10.1016\/j.jaip.2026.01.022_bib114","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1067\/mai.2003.1388","article-title":"Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial","volume":"111","author":"Wark","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.prrv.2012.11.004","article-title":"Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis","volume":"14","author":"Wong","year":"2013","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jaip.2026.01.022_bib116","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/thx.2004.035519","article-title":"Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody","volume":"62","author":"van der Ent","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2026.01.022_bib117","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/ppul.20804","article-title":"Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis","volume":"43","author":"Zirbes","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2026.01.022_bib118","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/ppul.20907","article-title":"Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab)","volume":"43","author":"Kanu","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2026.01.022_bib119","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/02770900902849871","article-title":"Resolution of corticosteroid-induced diabetes in allergic bronchopulmonary aspergillosis with omalizumab therapy: a novel approach","volume":"46","author":"Randhawa","year":"2009","journal-title":"J Asthma"},{"key":"10.1016\/j.jaip.2026.01.022_bib120","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.07.2008.0379","article-title":"Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis","volume":"2009","author":"Lebecque","year":"2009","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib121","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.arbres.2008.05.007","article-title":"Effective anti-immunoglobulin-E antibody treatment of a patient with allergic bronchopulmonary aspergillosis [article in Spanish]","volume":"45","author":"Quint\u00e1s V\u00e1zquez","year":"2009","journal-title":"Arch Bronconeumol"},{"issue":"suppl 1","key":"10.1016\/j.jaip.2026.01.022_bib122","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1258\/jrsm.2009.s19011","article-title":"Life-threatening allergic bronchopulmonary aspergillosis treated with methylprednisolone and anti-IgE monoclonal antibody","volume":"102","author":"Thomas","year":"2009","journal-title":"J R Soc Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib123","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3109\/02770903.2010.491144","article-title":"Measured immunoglobulin E in allergic bronchopulmonary aspergillosis treated with omalizumab","volume":"47","author":"Lin","year":"2010","journal-title":"J Asthma"},{"key":"10.1016\/j.jaip.2026.01.022_bib124","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1398-9995.2009.02147.x","article-title":"Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis","volume":"65","author":"Brinkmann","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bib125","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1398-9995.2011.02599.x","article-title":"Allergic bronchopulmonary aspergillosis and omalizumab","volume":"66","author":"Tillie-Leblond","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bib126","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/thx.2010.153312","article-title":"Effects of omalizumab in Aspergillus-associated airway disease","volume":"66","author":"P\u00e9rez-de-Llano","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2026.01.022_bib127","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/JAA.S34579","article-title":"Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab","volume":"5","author":"Collins","year":"2012","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bib128","first-page":"145","article-title":"A case of allergic bronchopulmonary aspergillosis treated with omalizumab","volume":"22","author":"Sastre","year":"2012","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib129","first-page":"88","article-title":"Management of patients with cystic fibrosis and allergic bronchopulmonary aspergillosis using anti-immunoglobulin e therapy (omalizumab)","volume":"17","author":"Elmallah","year":"2012","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1016\/j.jaip.2026.01.022_bib130","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1753465814547517","article-title":"Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis","volume":"8","author":"Lehmann","year":"2014","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jaip.2026.01.022_bib131","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jaip.2013.08.014","article-title":"Unexpected decrease in total IgE in a patient with allergic bronchopulmonary aspergillosis treated with omalizumab","volume":"2","author":"Wolf","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib132","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaip.2014.12.008","article-title":"Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis","volume":"3","author":"Voskamp","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib133","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2500\/aap.2015.36.3909","article-title":"Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: one center's experience with 14 cases","volume":"36","author":"Ayd\u0131n","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2026.01.022_bib134","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2500\/ar.2015.6.0128","article-title":"Steroid sparing effect of omalizumab in seropositive allergic bronchopulmonary aspergillosis","volume":"6","author":"Beam","year":"2015","journal-title":"Allergy Rhinol (Providence)"},{"key":"10.1016\/j.jaip.2026.01.022_bib135","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.anai.2015.06.014","article-title":"Omalizumab, an additional therapy for allergic bronchopulmonary aspergillosis","volume":"115","author":"Evans","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib136","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.medcli.2014.05.020","article-title":"Role of omalizumab in the management of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis [article in Spanish]","volume":"144","author":"Delgado Pecell\u00edn","year":"2015","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.jaip.2026.01.022_bib137","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jaip.2015.11.014","article-title":"Following total IgE concentration in patients with allergic bronchopulmonary aspergillosis on omalizumab","volume":"4","author":"Kelso","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib138","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/1060028015624204","article-title":"Omalizumab treatment for allergic bronchopulmonary aspergillosis in cystic fibrosis","volume":"50","author":"Emiralioglu","year":"2016","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaip.2026.01.022_bib139","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ppul.23612","article-title":"Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients","volume":"52","author":"Nov\u00e9-Josserand","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2026.01.022_bib140","first-page":"304","article-title":"Allergic bronchopulmonary aspergillosis treated successfully with omalizumab","volume":"23","author":"Aguiar","year":"2017","journal-title":"Rev Port Pneumol"},{"key":"10.1016\/j.jaip.2026.01.022_bib141","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.rmed.2017.11.007","article-title":"Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis","volume":"133","author":"Perisson","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib142","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1590\/s1806-37562017000000325","article-title":"Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis","volume":"44","author":"Cunha","year":"2018","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.jaip.2026.01.022_bib143","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/JAA.S156049","article-title":"Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis","volume":"11","author":"Ashkenazi","year":"2018","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bib144","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jaip.2019.01.056","article-title":"Successful treatment with omalizumab of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: case reports and literature review","volume":"7","author":"Parisi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib145","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcf.2019.07.011","article-title":"Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosis","volume":"19","author":"Koutsokera","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jaip.2026.01.022_bib146","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1016\/j.jaip.2020.05.055","article-title":"Omalizumab is an effective intervention in severe asthma with fungal sensitization","volume":"8","author":"Wark","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib147","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1159\/000507216","article-title":"Effectiveness and safety of omalizumab in patients with allergic bronchopulmonary aspergillosis complicated by chronic bacterial infection in the airways","volume":"181","author":"Tomomatsu","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib148","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12890-023-02696-x","article-title":"Effectiveness and safety of omalizumab in patients with allergic bronchopulmonary aspergillosis with or without allergic rhinitis: a retrospective chart review","volume":"23","author":"Cai","year":"2023","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib149","doi-asserted-by":"crossref","first-page":"26","DOI":"10.23822\/EurAnnACI.1764-1489.261","article-title":"Can dose reduction be made in patients with allergic bronchopulmonary aspergillosis receiving high-dose omalizumab treatment?","volume":"56","author":"Korkmaz","year":"2024","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib150","article-title":"Case Report: Omalizumab combined with voriconazole for the treatment of ABPA complicating IPA: a case report","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2026.01.022_bib152","author":"Novartis"},{"key":"10.1016\/j.jaip.2026.01.022_bib153","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12890-018-0617-5","article-title":"A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab","volume":"18","author":"Terashima","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib154","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.alit.2018.03.004","article-title":"Severe asthma concomitant with allergic bronchopulmonary aspergillosis successfully treated with mepolizumab","volume":"67","author":"Oda","year":"2018","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2026.01.022_bib155","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.alit.2018.12.008","article-title":"Case series of allergic bronchopulmonary aspergillosis treated successfully and safely with long-term mepolizumab","volume":"68","author":"Soeda","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2026.01.022_bib156","article-title":"Successful treatment with mepolizumab in a case of allergic bronchopulmonary aspergillosis complicated with nontuberculous mycobacterial infection","volume":"28","author":"Tsubouchi","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib157","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.465","article-title":"Allergic bronchopulmonary aspergillosis complicated by eosinophilic chronic rhinosinusitis successfully treated with mepolizumab","volume":"7","author":"Matsumoto","year":"2019","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib158","article-title":"Successful treatment with mepolizumab for allergic bronchopulmonary mycosis complicated with bilateral septic arthritis of the knee joints caused by methicillin-resistant Staphylococcus aureus","volume":"31","author":"Yanagihara","year":"2020","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib159","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jaip.2020.03.023","article-title":"Mepolizumab for allergic bronchopulmonary aspergillosis: report of 20 cases from the Belgian Severe Asthma Registry and review of the literature","volume":"8","author":"Schleich","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13223-019-0397-3","article-title":"Use of mepolizumab in adult patients with cystic fibrosis and an eosinophilic phenotype: case series","volume":"16","author":"Zhang","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib161","doi-asserted-by":"crossref","first-page":"215","DOI":"10.5578\/tt.20229815","article-title":"Severe asthma concomitant with allergic bronchopulmonary aspergillosis (ABPA) and non-steroid exacerbated respiratory disease (N-ERD) successfully treated with mepolizumab: a case report","volume":"70","author":"\u00c7akmak","year":"2022","journal-title":"Tuberk Toraks"},{"key":"10.1016\/j.jaip.2026.01.022_bib162","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejim.2021.12.026","article-title":"One-year mepolizumab for allergic bronchopulmonary aspergillosis: focus on steroid sparing effect and markers of response","volume":"99","author":"Caminati","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib163","article-title":"Mepolizumab in allergic bronchopulmonary aspergillosis complicated by infection","volume":"45","author":"Hamada","year":"2023","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110265","article-title":"Allergic bronchopulmonary aspergillosis in a lung transplant recipient treated with mepolizumab","volume":"264","author":"Ioakeim","year":"2024","journal-title":"Clin Immunol (Orlando)"},{"key":"10.1016\/j.jaip.2026.01.022_bib165","first-page":"352","article-title":"Mepolizumab improved airway hyperresponsiveness in a patient with allergic bronchopulmonary aspergillosis","volume":"43","author":"Onitsuka","year":"2025","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib166","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.696","article-title":"Mepolizumab use in cystic fibrosis-associated allergic bronchopulmonary aspergillosis","volume":"9","author":"Boyle","year":"2021","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib167","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.alit.2020.03.003","article-title":"Rapid clearance of mepolizumab-resistant bronchial mucus plugs in allergic bronchopulmonary aspergillosis with benralizumab treatment","volume":"69","author":"Tomomatsu","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2026.01.022_bib168","doi-asserted-by":"crossref","first-page":"378","DOI":"10.18176\/jiaci.0564","article-title":"Successful treatment of allergic bronchopulmonary aspergillosis with benralizumab in a patient who did not respond to omalizumab","volume":"30","author":"Bernal-Rubio","year":"2020","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib169","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/medicina58010053","article-title":"The use of targeted monoclonal antibodies in the treatment of ABPA-A case series","volume":"58","author":"O'Reilly","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.jaip.2026.01.022_bib170","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2169\/internalmedicine.6217-20","article-title":"Successful treatment with benralizumab for allergic bronchopulmonary aspergillosis that developed after disastrous heavy rainfall in Western Japan","volume":"60","author":"Matsuura","year":"2021","journal-title":"Int Med (Tokyo)"},{"key":"10.1016\/j.jaip.2026.01.022_bib171","article-title":"A case of allergic bronchopulmonary aspergillosis with marked peripheral blood eosinophilia successfully treated with benralizumab","volume":"32","author":"Tsubouchi","year":"2021","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib172","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.1167","article-title":"Rapid onset of effect of benralizumab in a severe eosinophilic and allergic asthma patient with allergic bronchopulmonary aspergillosis","volume":"11","author":"Alaga","year":"2023","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib174","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaip.2019.11.031","article-title":"Dupilumab treatment for allergic bronchopulmonary aspergillosis: a case series","volume":"8","author":"Ramonell","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib175","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13223-020-00454-w","article-title":"Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?","volume":"16","author":"M\u00fcmmler","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib176","doi-asserted-by":"crossref","DOI":"10.1093\/omcr\/omaa029","article-title":"Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis","volume":"2021","author":"Ali","year":"2021","journal-title":"Oxf Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib177","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.12998\/wjcc.v9.i23.6922","article-title":"Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: a case report","volume":"9","author":"Nishimura","year":"2021","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.jaip.2026.01.022_bib178","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.alit.2020.08.006","article-title":"Efficacy of dupilumab and biomarkers for systemic corticosteroid na\u00efve allergic bronchopulmonary mycosis","volume":"70","author":"Tashiro","year":"2021","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2026.01.022_bib179","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12081","article-title":"Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab","volume":"11","author":"van der Veer","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bib180","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.2169\/internalmedicine.6679-20","article-title":"Successful treatment of mepolizumab- and prednisolone-resistant allergic bronchopulmonary aspergillosis with dupilumab","volume":"60","author":"Mikura","year":"2021","journal-title":"Intern Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib181","article-title":"Successful management of recurrent allergic bronchopulmonary aspergillosis after changing from mepolizumab to dupilumab: a case report","volume":"39","author":"Kai","year":"2022","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib182","article-title":"A case of allergic bronchopulmonary aspergillosis with failure of benralizumab and response to dupilumab","volume":"15","author":"Kotetsu","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2026.01.022_bib183","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.jaip.2022.12.049","article-title":"Allergic bronchopulmonary aspergillosis in identical twins: effectiveness of dupilumab","volume":"11","author":"Lamothe","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib184","article-title":"Successful treatment of mucus plug due to allergic bronchopulmonary aspergillosis using dupilumab","volume":"16","author":"Sumi","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2026.01.022_bib185","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.1354","article-title":"Efficacy of dupilumab as an alternative to corticosteroids in the treatment of exacerbations of allergic bronchopulmonary aspergillosis","volume":"12","author":"Hamakawa","year":"2024","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib186","article-title":"Successful treatment with dupilumab in mepolizumab-resistant allergic bronchopulmonary aspergillosis","volume":"47","author":"Kawasaki","year":"2024","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib187","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.1432","article-title":"Development of allergic bronchopulmonary aspergillosis in a patient with nontuberculous mycobacterial-pulmonary disease successfully treated with dupilumab: a case report and literature review","volume":"12","author":"Onozato","year":"2024","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib188","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jaip.2024.04.018","article-title":"A case of allergic bronchopulmonary aspergillosis in a child: response to dupilumab","volume":"12","author":"Meneses","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib189","article-title":"Efficacy and safety of dupilumab treatment for adult allergic bronchopulmonary aspergillosis: a real-world analysis of 16 cases in China","author":"Li","year":"2026","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bib190","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A5230","article-title":"Dupilumab improves lung function, asthma control and exacerbation frequency in allergic bronchopulmonary aspergillosis - results from the phase 2 LIBERTY ABPA AIRED study","volume":"211","author":"Bourdin","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2026.01.022_bib191","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jaip.2017.01.013","article-title":"Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis","volume":"5","author":"Altman","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib192","first-page":"59","article-title":"Allergic bronchopulmonary aspergillosis successfully treated with mepolizumab: case report and review of the literature","volume":"26","author":"Hirota","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib193","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jaip.2021.02.048","article-title":"Real-world effectiveness of anti-IL-5\/5R therapy in severe atopic eosinophilic asthma with fungal sensitization","volume":"9","author":"Dhariwal","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bib194","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1038\/s41598-023-32246-8","article-title":"Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis","volume":"13","author":"Tomomatsu","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bib195","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.anai.2025.06.006","article-title":"Paradoxical effects of dupilumab in allergic bronchopulmonary aspergillosis: resolution of mucus plugging but induction of eosinophilic pneumonia","volume":"135","author":"Matsuno","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bib196","article-title":"Anti-IL-4Ra therapy is superior to other biologic classes in treating allergic bronchopulmonary aspergillosis","volume":"4","author":"Lamothe","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaip.2026.01.022_bib197","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jaip.2025.03.006","article-title":"Real-world effectiveness of biologic therapy in allergic bronchopulmonary aspergillosis","volume":"13","author":"Carter","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bibE1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3346\/jkms.2012.27.10.1261","article-title":"Successful treatment of chronic eosinophilic pneumonia with anti-IgE therapy","volume":"27","author":"Shin","year":"2012","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jaip.2026.01.022_bibE2","doi-asserted-by":"crossref","DOI":"10.1378\/chest.12-2035","article-title":"Can omalizumab be effective in chronic eosinophilic pneumonia?","volume":"143","author":"Domingo","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2026.01.022_bibE3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1378\/chest.11-1881","article-title":"Omalizumab as a steroid-sparing agent in chronic eosinophilic pneumonia","volume":"142","author":"Kaya","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2026.01.022_bibE4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.arbr.2018.05.004","article-title":"Response to omalizumab in a patient with chronic eosinophilic pneumonia and poor response to corticosteroids","volume":"54","author":"Lavi\u00f1a-Soriano","year":"2018","journal-title":"Arch Bronconeumol (Engl Ed)"},{"key":"10.1016\/j.jaip.2026.01.022_bibE5","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/02770903.2018.1534966","article-title":"Favorable response to asthma-dosed subcutaneous mepolizumab in eosinophilic pneumonia","volume":"56","author":"Lin","year":"2019","journal-title":"J Asthma"},{"key":"10.1016\/j.jaip.2026.01.022_bibE6","article-title":"A case of relapsing chronic eosinophilic pneumonia treated by Omalizumab","volume":"41","author":"Nehme","year":"2023","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00408-020-00336-3","article-title":"Real-life study of mepolizumab in idiopathic chronic eosinophilic pneumonia","volume":"198","author":"Brenard","year":"2020","journal-title":"Lung"},{"key":"10.1016\/j.jaip.2026.01.022_bibE8","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2021.07.1160","article-title":"When steroids fail: a population-based review of biologic therapies in the management of recalcitrant eosinophilic pneumonia","volume":"160","author":"Askin","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2026.01.022_bibE9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/JAA.S343272","article-title":"Anti-IL-5 agents for the treatment of idiopathic chronic eosinophilic pneumonia: a case series","volume":"15","author":"Tashiro","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bibE10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/02770903.2018.1543434","article-title":"Anti-interleukin (IL)-5 as a steroid-sparing agent in chronic eosinophilic pneumonia","volume":"57","author":"Sarkis","year":"2020","journal-title":"J Asthma"},{"key":"10.1016\/j.jaip.2026.01.022_bibE11","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1016\/j.jaip.2020.06.053","article-title":"Effect of mepolizumab alone in chronic eosinophilic pneumonia relapse: a case report","volume":"8","author":"Ciuffreda","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bibE12","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2020.08.1010","article-title":"Steroid dependent chronic eosinophilic pneumonia: a win for IL-5 antagnonism in an active duty service member","volume":"158","author":"Askin","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2026.01.022_bibE13","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.7573\/dic.2020-5-3","article-title":"Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance","volume":"9","author":"Kisling","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.jaip.2026.01.022_bibE14","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.514","article-title":"Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty","volume":"8","author":"Otoshi","year":"2020","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.18176\/jiaci.0671","article-title":"Efficacy of mepolizumab extended interval dosing for 2 asthmatic patients with chronic eosinophilic pneumonia","volume":"31","author":"Sato","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE16","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2021.08.271","article-title":"M122 Mepolizumab: A steroid alternative for chronic eosinophilic pneumonia","volume":"127","author":"Benipal","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE17","article-title":"Mepolizumab and dupilumab as a replacement to systemic glucocorticoids for the treatment of chronic eosinophilic pneumonia and allergic bronchopulmonary aspergillosis - case series, Almoosa specialist hospital","volume":"34","author":"Eldaabossi","year":"2021","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE18","article-title":"Chronic eosinophilic pneumonia: when corticosteroids are not enough","volume":"203","author":"Mckillion","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2026.01.022_bibE19","series-title":"Successful use of mepolizumab for steroid-dependent chronic eosinophilic pneumonia","author":"Cyca","year":"2022"},{"key":"10.1016\/j.jaip.2026.01.022_bibE20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.12688\/f1000research.130939.3","article-title":"Case report: mepolizumab in the treatment of idiopathic chronic eosinophilic pneumonia","volume":"12","author":"Daboussi","year":"2023","journal-title":"F1000Res"},{"key":"10.1016\/j.jaip.2026.01.022_bibE21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00508-024-02406-5","article-title":"Healing chronic idiopathic eosinophilic pneumonia using mepolizumab alone without corticosteroids","volume":"137","author":"Moritz","year":"2025","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.jaip.2026.01.022_bibE22","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.jaip.2018.06.017","article-title":"A case of chronic eosinophilic pneumonia successfully treated with mepolizumab","volume":"6","author":"To","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bibE23","article-title":"Chronic eosinophilic pneumonia and new biological therapies [article in Spanish]","volume":"3","author":"Morena Valles","year":"2021","journal-title":"Open Respir Arch"},{"key":"10.1016\/j.jaip.2026.01.022_bibE24","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.12998\/wjcc.v10.i18.6105","article-title":"Successful treatment of acute relapse of chronic eosinophilic pneumonia with benralizumab and without corticosteroids: a case report","volume":"10","author":"Izhakian","year":"2022","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.jaip.2026.01.022_bibE25","article-title":"Two years follow-up of relapsing eosinophilic pneumonia with concomitant severe asthma successfully treated with benralizumab: a case report and brief review of the literature","volume":"41","author":"Angeletti","year":"2023","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE26","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.810","article-title":"Benralizumab use in chronic eosinophilic pneumonia with eosinophilic bronchiolitis and chronic airway infection","volume":"9","author":"Takano","year":"2021","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE27","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.anai.2021.02.016","article-title":"Relapsing chronic eosinophilic pneumonia treated successfully with benralizumab","volume":"126","author":"Ricketti","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE28","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.alit.2020.07.005","article-title":"Benralizumab as initial treatment for chronic eosinophilic pneumonia","volume":"70","author":"Yazawa","year":"2021","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2026.01.022_bibE29","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1002\/ppul.25511","article-title":"Reverse butterfly pattern image with eosinophilia: effective treatment with benralizumab-a case report","volume":"56","author":"Ben-David","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE30","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2019.08.436","article-title":"M401 Benralizumab for unresponsive steroid-dependent chronic eosinophilic pneumonia","volume":"123","author":"Garcia-Saucedo","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE31","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2169\/internalmedicine.3606-19","article-title":"Promising effects of benralizumab on chronic eosinophilic pneumonia","volume":"59","author":"Isomoto","year":"2020","journal-title":"Intern Med"},{"key":"10.1016\/j.jaip.2026.01.022_bibE32","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2020.05.195","article-title":"Eosinophilic pneumonia when steroids are not the answer: case report","volume":"157","author":"Braga","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2026.01.022_bibE33","article-title":"Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia","volume":"30","author":"Izumo","year":"2020","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE34","article-title":"Exploring the efficacy of benralizumab in chronic eosinophilic pneumonia following corticosteroid therapeutic failure: a case report","volume":"17","author":"De La O Villalobos","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2026.01.022_bibE35","article-title":"Benralizumab treatment and 3-dimensional bronchial tree changes in chronic eosinophilic pneumonia","volume":"4","author":"Kai","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaip.2026.01.022_bibE36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.18176\/jiaci.0468","article-title":"Long-term treatment with anti-interleukin 5 antibodies in a patient with chronic eosinophilic pneumonia","volume":"30","author":"Shimizu","year":"2020","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE37","first-page":"857","article-title":"Dupilumab suppresses relapsing chronic eosinophilic pneumonia with severe asthma","volume":"85","author":"Masumoto","year":"2023","journal-title":"Nagoya J Med Sci"},{"key":"10.1016\/j.jaip.2026.01.022_bibE38","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1002\/ppul.25096","article-title":"Dupilumab for chronic eosinophilic pneumonia","volume":"55","author":"Fowler","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/thx.2004.035519","article-title":"Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody","volume":"62","author":"van der Ent","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2026.01.022_bibE40","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/ppul.20804","article-title":"Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis","volume":"43","author":"Zirbes","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE41","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/ppul.20907","article-title":"Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab)","volume":"43","author":"Kanu","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE42","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/02770900902849871","article-title":"Resolution of corticosteroid-induced diabetes in allergic bronchopulmonary aspergillosis with omalizumab therapy: a novel approach","volume":"46","author":"Randhawa","year":"2009","journal-title":"J Asthma"},{"key":"10.1016\/j.jaip.2026.01.022_bibE43","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.07.2008.0379","article-title":"Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis","volume":"2009","author":"Lebecque","year":"2009","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.arbres.2008.05.007","article-title":"Effective anti-immunoglobulin-E antibody treatment of a patient with allergic bronchopulmonary aspergillosis [article in Spanish]","volume":"45","author":"Quint\u00e1s V\u00e1zquez","year":"2009","journal-title":"Arch Bronconeumol"},{"issue":"suppl 1","key":"10.1016\/j.jaip.2026.01.022_bibE45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1258\/jrsm.2009.s19011","article-title":"Life-threatening allergic bronchopulomnary aspergillosis treated with methylprednisolone and anti-IgE monoclonal antibody","volume":"102","author":"Thomas","year":"2009","journal-title":"J R Soc Med"},{"key":"10.1016\/j.jaip.2026.01.022_bibE46","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3109\/02770903.2010.491144","article-title":"Measured immunoglobulin E in allergic bronchopulmonary aspergillosis treated with omalizumab","volume":"47","author":"Lin","year":"2010","journal-title":"J Asthma"},{"key":"10.1016\/j.jaip.2026.01.022_bibE47","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1398-9995.2009.02147.x","article-title":"Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis","volume":"65","author":"Brinkmann","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bibE48","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1398-9995.2011.02599.x","article-title":"Allergic bronchopulmonary aspergillosis and omalizumab","volume":"66","author":"Tillie-Leblond","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bibE49","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/thx.2010.153312","article-title":"Effects of omalizumab in Aspergillus-associated airway disease","volume":"66","author":"P\u00e9rez-de-Llano","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2026.01.022_bibE50","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/JAA.S34579","article-title":"Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab","volume":"5","author":"Collins","year":"2012","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bibE51","first-page":"145","article-title":"A case of allergic bronchopulmonary aspergillosis treated with omalizumab","volume":"22","author":"Sastre","year":"2012","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE52","first-page":"88","article-title":"Management of patients with cystic fibrosis and allergic bronchopulmonary aspergillosis using anti-immunoglobulin e therapy (omalizumab)","volume":"17","author":"Elmallah","year":"2012","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1016\/j.jaip.2026.01.022_bibE53","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jaip.2013.08.014","article-title":"Unexpected decrease in total IgE in a patient with allergic bronchopulmonary aspergillosis treated with omalizumab","volume":"2","author":"Wolf","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bibE54","first-page":"1839","article-title":"Anti IgE antibody as treatment of allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis","volume":"18","author":"Zicari","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jaip.2026.01.022_bibE55","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1753465814547517","article-title":"Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis","volume":"8","author":"Lehmann","year":"2014","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jaip.2026.01.022_bibE56","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaip.2014.12.008","article-title":"Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis","volume":"3","author":"Voskamp","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bibE57","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2500\/aap.2015.36.3909","article-title":"Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: one center's experience with 14 cases","volume":"36","author":"Ayd\u0131n","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2026.01.022_bibE58","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2500\/ar.2015.6.0128","article-title":"Steroid sparing effect of omalizumab in seropositive allergic bronchopulmonary aspergillosis","volume":"6","author":"Beam","year":"2015","journal-title":"Allergy Rhinol (Providence)"},{"key":"10.1016\/j.jaip.2026.01.022_bibE59","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.anai.2015.06.014","article-title":"Omalizumab, an additional therapy for allergic bronchopulmonary aspergillosis","volume":"115","author":"Evans","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE60","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.medcli.2014.05.020","article-title":"Role of omalizumab in the management of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis [article in Spanish]","volume":"144","author":"Delgado Pecell\u00edn","year":"2015","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.jaip.2026.01.022_bibE61","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1165\/rcmb.2015-0062OC","article-title":"Role of Aspergillus fumigatus in triggering protease-activated receptor-2 in airway epithelial cells and skewing the cells toward a T-helper 2 bias","volume":"54","author":"Homma","year":"2016","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE62","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jaip.2015.11.014","article-title":"Following total IgE concentration in patients with allergic bronchopulmonary aspergillosis on omalizumab","volume":"4","author":"Kelso","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bibE63","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/1060028015624204","article-title":"Omalizumab treatment for allergic bronchopulmonary aspergillosis in cystic fibrosis","volume":"50","author":"Emiralioglu","year":"2016","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaip.2026.01.022_bibE64","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ppul.23612","article-title":"Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients","volume":"52","author":"Nov\u00e9-Josserand","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE65","first-page":"304","article-title":"Allergic bronchopulmonary aspergillosis treated successfully with omalizumab","volume":"23","author":"Aguiar","year":"2017","journal-title":"Rev Port Pneumol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE66","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.rmed.2017.11.007","article-title":"Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis","volume":"133","author":"Perisson","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2026.01.022_bibE67","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1590\/s1806-37562017000000325","article-title":"Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis","volume":"44","author":"Cunha","year":"2018","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE68","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/JAA.S156049","article-title":"Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis","volume":"11","author":"Ashkenazi","year":"2018","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bibE69","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jaip.2019.01.056","article-title":"Successful treatment with omalizumab of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: case reports and literature review","volume":"7","author":"Parisi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bibE70","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcf.2019.07.011","article-title":"Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosis","volume":"19","author":"Koutsokera","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jaip.2026.01.022_bibE71","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1016\/j.jaip.2020.05.055","article-title":"Omalizumab is an effective intervention in severe asthma with fungal sensitization","volume":"8","author":"Wark","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bibE72","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1159\/000507216","article-title":"Effectiveness and safety of omalizumab in patients with allergic bronchopulmonary aspergillosis complicated by chronic bacterial infection in the airways","volume":"181","author":"Tomomatsu","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE73","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12890-023-02696-x","article-title":"Effectiveness and safety of omalizumab in patients with allergic bronchopulmonary aspergillosis with or without allergic rhinitis: a retrospective chart review","volume":"23","author":"Cai","year":"2023","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaip.2026.01.022_bibE74","doi-asserted-by":"crossref","first-page":"26","DOI":"10.23822\/EurAnnACI.1764-1489.261","article-title":"Can dose reduction be made in patients with allergic bronchopulmonary aspergillosis receiving high-dose omalizumab treatment?","volume":"56","author":"Korkmaz","year":"2024","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE75","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s10238-023-01267-y","article-title":"Efficacy of omalizumab in adult patients with allergic bronchopulmonary aspergillosis: a multicentre study in China","volume":"24","author":"Chen","year":"2024","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.jaip.2026.01.022_bibE76","article-title":"Case Report: Omalizumab combined with voriconazole for the treatment of ABPA complicating IPA: a case report","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE78","author":"Novartis"},{"key":"10.1016\/j.jaip.2026.01.022_bibE79","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12890-018-0617-5","article-title":"A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab","volume":"18","author":"Terashima","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaip.2026.01.022_bibE80","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.alit.2018.03.004","article-title":"Severe asthma concomitant with allergic bronchopulmonary aspergillosis successfully treated with mepolizumab","volume":"67","author":"Oda","year":"2018","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2026.01.022_bibE81","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.alit.2018.12.008","article-title":"Case series of allergic bronchopulmonary aspergillosis treated successfully and safely with long-term mepolizumab","volume":"68","author":"Soeda","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2026.01.022_bibE82","article-title":"Successful treatment with mepolizumab in a case of allergic bronchopulmonary aspergillosis complicated with nontuberculous mycobacterial infection","volume":"28","author":"Tsubouchi","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE83","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.465","article-title":"Allergic bronchopulmonary aspergillosis complicated by eosinophilic chronic rhinosinusitis successfully treated with mepolizumab","volume":"7","author":"Matsumoto","year":"2019","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE84","article-title":"Successful treatment with mepolizumab for allergic bronchopulmonary mycosis complicated with bilateral septic arthritis of the knee joints caused by methicillin-resistant Staphylococcus aureus","volume":"31","author":"Yanagihara","year":"2020","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE85","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jaip.2020.03.023","article-title":"Mepolizumab for allergic bronchopulmonary aspergillosis: report of 20 cases from the Belgian Severe Asthma Registry and review of the literature","volume":"8","author":"Schleich","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bibE86","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13223-019-0397-3","article-title":"Use of mepolizumab in adult patients with cystic fibrosis and an eosinophilic phenotype: case series","volume":"16","author":"Zhang","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE87","doi-asserted-by":"crossref","first-page":"215","DOI":"10.5578\/tt.20229815","article-title":"Severe asthma concomitant with allergic bronchopulmonary aspergillosis (ABPA) and non-steroid exacerbated respiratory disease (N-ERD) successfully treated with mepolizumab: a case report","volume":"70","author":"\u00c7akmak","year":"2022","journal-title":"Tuberk Toraks"},{"key":"10.1016\/j.jaip.2026.01.022_bibE88","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejim.2021.12.026","article-title":"One-year mepolizumab for allergic bronchopulmonary aspergillosis: focus on steroid sparing effect and markers of response","volume":"99","author":"Caminati","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaip.2026.01.022_bibE89","article-title":"Mepolizumab in allergic bronchopulmonary aspergillosis complicated by infection","volume":"45","author":"Hamada","year":"2023","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE90","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110265","article-title":"Allergic bronchopulmonary aspergillosis in a lung transplant recipient treated with mepolizumab","volume":"264","author":"Ioakeim","year":"2024","journal-title":"Clin Immunol (Orlando)"},{"key":"10.1016\/j.jaip.2026.01.022_bibE91","first-page":"352","article-title":"Mepolizumab improved airway hyperresponsiveness in a patient with allergic bronchopulmonary aspergillosis","volume":"43","author":"Onitsuka","year":"2025","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE92","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jaip.2017.01.013","article-title":"Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis","volume":"5","author":"Altman","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bibE93","first-page":"59","article-title":"Allergic bronchopulmonary aspergillosis successfully treated with mepolizumab: case report and review of the literature","volume":"26","author":"Hirota","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE94","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.696","article-title":"Mepolizumab use in cystic fibrosis-associated allergic bronchopulmonary aspergillosis","volume":"9","author":"Boyle","year":"2021","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE95","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jaip.2018.11.024","article-title":"Allergic bronchopulmonary aspergillosis successfully treated with benralizumab","volume":"7","author":"Soeda","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bibE96","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.alit.2020.03.003","article-title":"Rapid clearance of mepolizumab-resistant bronchial mucus plugs in allergic bronchopulmonary aspergillosis with benralizumab treatment","volume":"69","author":"Tomomatsu","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2026.01.022_bibE97","doi-asserted-by":"crossref","first-page":"378","DOI":"10.18176\/jiaci.0564","article-title":"Successful treatment of allergic bronchopulmonary aspergillosis with benralizumab in a patient who did not respond to omalizumab","volume":"30","author":"Bernal-Rubio","year":"2020","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE98","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/medicina58010053","article-title":"The use of targeted monoclonal antibodies in the treatment of ABPA-A case series","volume":"58","author":"O'Reilly","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.jaip.2026.01.022_bibE99","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2169\/internalmedicine.6217-20","article-title":"Successful treatment with benralizumab for allergic bronchopulmonary aspergillosis that developed after disastrous heavy rainfall in Western Japan","volume":"60","author":"Matsuura","year":"2021","journal-title":"Int Med (Tokyo)"},{"key":"10.1016\/j.jaip.2026.01.022_bibE100","article-title":"A case of allergic bronchopulmonary aspergillosis with marked peripheral blood eosinophilia successfully treated with benralizumab","volume":"32","author":"Tsubouchi","year":"2021","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE101","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.1167","article-title":"Rapid onset of effect of benralizumab in a severe eosinophilic and allergic asthma patient with allergic bronchopulmonary aspergillosis","volume":"11","author":"Alaga","year":"2023","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE102","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jaip.2021.02.048","article-title":"Real-world effectiveness of anti-IL-5\/5R therapy in severe atopic eosinophilic asthma with fungal sensitization","volume":"9","author":"Dhariwal","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bibE103","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1038\/s41598-023-32246-8","article-title":"Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis","volume":"13","author":"Tomomatsu","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE105","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaip.2019.11.031","article-title":"Dupilumab treatment for allergic bronchopulmonary aspergillosis: a case series","volume":"8","author":"Ramonell","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bibE106","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13223-020-00454-w","article-title":"Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?","volume":"16","author":"M\u00fcmmler","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE107","doi-asserted-by":"crossref","DOI":"10.1093\/omcr\/omaa029","article-title":"Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis","volume":"2021","author":"Ali","year":"2021","journal-title":"Oxf Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE108","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.12998\/wjcc.v9.i23.6922","article-title":"Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: a case report","volume":"9","author":"Nishimura","year":"2021","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.jaip.2026.01.022_bibE109","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.alit.2020.08.006","article-title":"Efficacy of dupilumab and biomarkers for systemic corticosteroid na\u00efve allergic bronchopulmonary mycosis","volume":"70","author":"Tashiro","year":"2021","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2026.01.022_bibE110","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12081","article-title":"Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab","volume":"11","author":"van der Veer","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bibE111","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.2169\/internalmedicine.6679-20","article-title":"Successful treatment of mepolizumab- and prednisolone-resistant allergic bronchopulmonary aspergillosis with dupilumab","volume":"60","author":"Mikura","year":"2021","journal-title":"Intern Med"},{"key":"10.1016\/j.jaip.2026.01.022_bibE112","article-title":"Successful management of recurrent allergic bronchopulmonary aspergillosis after changing from mepolizumab to dupilumab: a case report","volume":"39","author":"Kai","year":"2022","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE113","article-title":"A case of allergic bronchopulmonary aspergillosis with failure of benralizumab and response to dupilumab","volume":"15","author":"Kotetsu","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2026.01.022_bibE114","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.jaip.2022.12.049","article-title":"Allergic bronchopulmonary aspergillosis in identical twins: effectiveness of dupilumab","volume":"11","author":"Lamothe","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bibE115","article-title":"Successful treatment of mucus plug due to allergic bronchopulmonary aspergillosis using dupilumab","volume":"16","author":"Sumi","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2026.01.022_bibE116","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.1354","article-title":"Efficacy of dupilumab as an alternative to corticosteroids in the treatment of exacerbations of allergic bronchopulmonary aspergillosis","volume":"12","author":"Hamakawa","year":"2024","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE117","article-title":"Successful treatment with dupilumab in mepolizumab-resistant allergic bronchopulmonary aspergillosis","volume":"47","author":"Kawasaki","year":"2024","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE118","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.1432","article-title":"Development of allergic bronchopulmonary aspergillosis in a patient with nontuberculous mycobacterial-pulmonary disease successfully treated with dupilumab: a case report and literature review","volume":"12","author":"Onozato","year":"2024","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE119","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jaip.2024.04.018","article-title":"A case of allergic bronchopulmonary aspergillosis in a child: response to dupilumab","volume":"12","author":"Meneses","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bibE120","article-title":"Efficacy and safety of dupilumab treatment for adult allergic bronchopulmonary aspergillosis: a real-world analysis of 16 cases in China","author":"Li","year":"2026","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2026.01.022_bibE212","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.anai.2025.06.006","article-title":"Paradoxical effects of dupilumab in allergic bronchopulmonary aspergillosis: resolution of mucus plugging but induction of eosinophilic pneumonia","volume":"135","author":"Matsuno","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.01.022_bibE122","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A5230","article-title":"Dupilumab improves lung function, asthma control and exacerbation frequency in allergic bronchopulmonary aspergillosis - results from the phase 2 LIBERTY ABPA AIRED study","volume":"211","author":"Bourdin","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2026.01.022_bibE123","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.1147","article-title":"Tezepelumab treatment for allergic bronchopulmonary aspergillosis","volume":"11","author":"Ogata","year":"2023","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jaip.2026.01.022_bibE124","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.jaip.2023.05.026","article-title":"Allergic bronchopulmonary aspergillosis successfully treated with tezepelumab","volume":"11","author":"Matsuno","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.01.022_bibE125","article-title":"Anti-IL-4Ra therapy is superior to other biologic classes in treating allergic bronchopulmonary aspergillosis","volume":"4","author":"Lamothe","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaip.2026.01.022_bibE126","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jaip.2025.03.006","article-title":"Real-world effectiveness of biologic therapy in allergic bronchopulmonary aspergillosis","volume":"13","author":"Carter","year":"2025","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826000590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826000590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:52:29Z","timestamp":1781265149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219826000590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":327,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2213219826000590"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2026.01.022","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics Use in Eosinophilic Lung Disease: Controversies and Consensus","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2026.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}